Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

REVISED EXPECTED TIMETABLE IN RELATION TO (I) PROPOSED CAPITAL REORGANISATION; AND (II) CONNECTED TRANSACTION FOR PROPOSED ALTERATION TO THE TERMS OF THE EXISTING CONVERTIBLE BONDS

References are made to the circular (the "**Circular**") of Wai Chun Bio-Technology Limited (the "**Company**") dated 28 March 2025, and the announcements of the Company dated 23 April 2025 and 21 May 2025 (the "**Announcements**"). Unless otherwise defined or the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular and the Announcements.

REVISED EXPECTED TIMETABLE

Set out below is the revised expected timetable in relation to the Capital Reorganisation and the connected transaction for Alteration of Terms:

Event(s)	**Time and Date**
Latest date and time for lodging transfer(s) of the Existing Ordinary Shares in order to qualify for attending and voting at the EGM	4:00 p.m. on Tuesday, 24 June 2025
Closure of register of members of the Company for determining the entitlement to attend and Vote at the EGM (both dates inclusive)	Wednesday, 25 June 2025 to Monday, 30 June 2025
Latest date and time for lodging forms of proxy for the EGM	3:00 p.m. on Saturday, 28 June 2025

Record date for attendance and voting at the EGM . . . . . Monday, 30 June 2025

Expected time and date of the EGM . . . . . 3:00 p.m. on Monday, 30 June 2025

Publication of announcement of poll results of the EGM . . . . . Monday, 30 June 2025

The following events are conditional on the fulfilment of the conditions for the implementation of the Capital Reorganisation and therefore the dates are tentative only.

Expected effective date of the Capital Reorganisation . . . . . Friday, 12 September 2025

Dealing in the New Ordinary Shares commences . . . . . 9:00 a.m. on Friday, 12 September 2025

EXTENSION OF LONG STOP DATE IN RELATION TO THE ALTERATION CONSENT LETTERS

Pursuant to the Alteration Consent Letters, the supplemental letters, the second supplemental letters, the third supplemental letters and the fourth supplemental letters, completion of the Alteration of Terms is conditional upon and subject to all the conditions precedent thereto being fulfilled or waived on or before the Long Stop Date, i.e. 29 August 2025. As additional time is required to procure the fulfillment of the conditions precedent, the Company and the Existing Bondholders entered into fifth supplemental letters on 21 August 2025 (after trading hours) for further extension of the Long Stop Date to 30 September 2025 (or such later date as may be agreed by the Company and the Existing Bondholders) for each Alteration Consent Letters. Save as disclosed in this announcement, all other terms and conditions of the Alteration Consent Letters remain unchanged and in full force and effect.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Chief Executive Officer

Hong Kong, 21 August 2025

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer) and three independent non-executive Directors, namely Mr. Wang Ziniu, Ms. Xu Huiling and Mr. Wong Po Keung.